Abstract
Renal cell carcinoma represents more than 90 % of all malignant kidney tumors. International guidelines for follow-up examinations after surgery for kidney tumors are still incomplete. New challenges are arising because of growing use of nephron sparing surgery. According to well-known prognosticators risk-adapted follow-up strategies may be established that are stratified into 3 risk groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
